Research and Development

I consult for a number of ongoing biotechnology R&D projects including Athla LLC/ HealthLabs, a discovery automation company for Big Data leveraging Big Compute.

Get in touch for troubleshooting/ insight within your discovery phase/ preclinical healthcare research program and for program development consultation.

Interested in developing products based on traditional medicines/ medicinal plants.

Startup Due Diligence

Experienced in evaluating investment opportunities on the Propel(x) platform – addressed investor questions and shared insights on the fundraising company’s breakthrough science & technology, market size, and competitive landscape.

Propel(x) is an angel investment platform exclusively focused on funding ‘deep technology’ startups – companies founded on a scientific discovery or meaningful engineering innovation.

Technical/ Scientific Writing

I provide the following:

  • Grant writing/ editing
  • Article writing/ editing
  • White papers
  • Web content
  • Manuscript editing
  • Copy editing
  • Technical/ scientific English


Get in touch with specific requirements and for pricing information/ quotes.


Journal Publications:

  1. Orchard-Webb D. 2016. Progress Toward Commercial Scale and Efficiency in Cell Therapy Bioprocessing. BioProcess International. October Supplement.
  1. Orchard-Webb D. 2015. Future Directions in Pancreatic Cancer Therapy. JOP. Journal of the Pancreas 16:249-255.
  1. Orchard-Webb D.J., Lee T.C., Cook G.P., Blair G.E. 2014. CUB Domain Containing Protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells. BMC Cancer. 14:754.
  1. Orchard-Webb D; Fox N; Elghazawy RM; Speirs V; Smith AM; Lodge JPA; Melcher AA; Verbeke CS; Blair GE. 2012. Development of a Chimaeric Oncolytic Adenovirus Vector for Pancreatic Cancer Biotherapy. Journal of pathology. 228: S18-S18.
  1. Elghazawy RM; Fox N; Orchard-Webb D; Speirs V; Smith AM; Lodge JPA; Verbeke CS; Blair GE. 2012. An Ex-Vivo Model of Human Pancreatic Cancer. Journal of pathology. 228: S19-S19.
  1. Orchard-Webb, D. 2011. The cancer cell biology of the integral membrane protein CUB domain containing protein 1 (CDCP1). University of Leeds. Thesis.
  1. Orchard-Webb, D. J., Cook, G. P., and Blair, G. E. 2010. Poster 482: Characterising the role of the metastasis associated cell surface glycoprotein CDCP1 in cancer cell lines – possible roles in cell adhesion and survival. EJC Supplements 8: 123.
  1. Fini, M.A., Orchard-Webb, D., Kosmider, B., Amon, J.D., Kelland, R., Shibao, G., and Wright, R.M. 2008. Migratory Activity of Human Breast Cancer Cells is Modulated by Differential Expression of Xanthine Oxidoreductase.  J. Cell. Biochem.  105: 1008-1026.


Web Publications:

  1. Orchard-Webb D. 2014. Next generation treatments for type I diabetes.



  1. Niebuhr M., Scharonow H., Gathmann M., Mamerow D., Werfel T. 2010. Staphylococcal exotoxins are strong inducers of IL-22: A potential role in atopic dermatitis. J Allergy Clin Immunol. 126: 1176-1183.e4.


David Orchard-Webb, PhD
LinkedIn Profile





Resource – STAT3 – Pancreatic Cancer


STAT3 plays a pivotal role in pancreatic cancer and is drawing increased attention as a potential drug target for the disease. This post will be updated periodically.


STAT3 inhibitors (1)Refs

MIR506 – Sun L, Hu L, Cogdell D, Lu L, Gao C, Tian W, Zhang Z, Kang Y, Fleming JB, Zhang W. MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway. Autophagy. 2017 Jan 25:0. doi: 10.1080/15548627.2017.1280217. PubMed PMID: 28121485.





AZD9150 – AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer. Identifier: NCT02983578

DHA – Park M, Kim H. Anti-cancer Mechanism of Docosahexaenoic Acid in Pancreatic Carcinogenesis: A Mini-review. J Cancer Prev. 2017 Mar;22(1):1-5. doi: 10.15430/JCP.2017.22.1.1. Epub 2017 Mar 30. Review. PubMed PMID: 28382280